MellowJoe

Free-form dancing, crypto for freedom dude!

[Martyupnorth®- Unacceptable Fact Checker @Martyupnorth]

Somewhere there's a farmer's kid with a real sense of humour. This is genius.

[Wall Street Mav @WallStreetMav]

I bought condoms at the pharmacy and the cashier asked if I wanted a bag.

I said, “no thanks. She’s not that ugly.”

[MellowJoe @MelllowJoe]

@ModernInvest $ADA

[✨₳DA ₿eacon⚡️ @AdaBeacon]

There's cryptographic decentralized block chains
and then there's everything else...

[AMERICA FIRST @01Patriot1776]

Ive got some demons I need to get rid of 🤣🤣🤣🤣🤣🤣

[Sarah Larchmont @SarahLarchmont]

God forbid a woman gets a hobby!

[🇺🇸 🦅Simple Man 🦅🇺🇸 @Soaringeagle45]

Funny 🤣😂😎

[Robert Karcher 🇵🇱🇩🇪🇪🇺 @Robert08938405]

Gdy jesteś dentystą i idziesz na randkę 😎

[Crazy Clips @crazyclips_]

The fact that this is an acceptable crossing guard response is frigging brilliant 🤣🤣🤣

[Jure @JureKaramarko]

⚠️

WHY DO THEY ATTACK CARDANO $ADA 👇

📝 @jasonappleton

[Interesting things @awkwardgoogle]

A father built this for his daughter and her friends.

[Bobbybollocks MP @Bobbybollocks2]

Good morning

[Planet Of Memes @PlanetOfMemes]

How much do you love your dog?

This much:

[Crazy Moments @Crazymoments01]

This is how this horse reacted to protect its caretaker during an earthquake in Japan.

[John F Kennedy Jr @John_F_kJr]

🚨 CONFIRMED: Epidemiologist Nicolas Hulscher Says IVERMECTIN and FENBENDAZOL Are Showing Documented Stage IV Cancer Remissions — Big Pharma Cannot Ignore This Anymore | VIDEO

🚨 A global medical firestorm is erupting after epidemiologist Nicolas Hulscher highlighted scientific reports documenting stage IV cancer remissions involving #ivermectin and #fenbendazole , reigniting worldwide debate over Big Pharma, alternative therapies, and the future of cancer treatment.

🚨 THE STAGE IV REMISSION CASES NOW SHOCKING THE MEDICAL WORLD

FOLLOW ME, THE NEXT DROP WILL BE SHOCKING.

[Brandon @LibOrNormal]

She just caught the biggest fish ever by a woman!

What is it called because I have no idea?

[Nicolas Hulscher, MPH @NicHulscher]

BREAKING: Largest Human Cancer Study of Ivermectin + Mebendazole Is Now PEER-REVIEWED and PUBLISHED in a MAJOR Cancer Journal

84.4% of cancer patients taking ivermectin + mebendazole for 6 months declared either CANCER DISAPPEARANCE, TUMOR REGRESSION, or CANCER STABILIZATION.

Our study, “Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort,” is now peer-reviewed and published in Anticancer Research—a major international oncology journal of the International Institute of Anticancer Research (IIAR), established in 1995.

The results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.

A diverse population of cancer patients (n=197) was prescribed compounded ivermectin–mebendazole through a U.S. telemedicine platform, with each capsule containing 25 mg ivermectin and 250 mg mebendazole.

Participants were followed for approximately six months using standardized digital surveys assessing cancer outcomes, medication adherence, and tolerability.

At approximately six months post-treatment initiation, we observed an 84.4% Clinical Benefit Ratio (CBR)—meaning more than four out of five patients reported either:
No evidence of disease (32.8%)
Tumor regression (15.6%)
or Cancer stabilization (36.1%)

Importantly, adherence was remarkably high, with 86.9% completing the initial prescription and 66.4% remaining on therapy at six months.

Side effects were predominantly mild and manageable, reported in 25.4% of patients (primarily gastrointestinal), with 93.6% of those experiencing side effects continuing treatment after minor dosing adjustments.

This groundbreaking peer-reviewed publication was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel—uniting real-world clinical data, frontline medical experience, and epidemiologic expertise to evaluate inexpensive, repurposed therapies with major translational potential.

With these extraordinarily promising results, double-blind, placebo-controlled clinical trials are now required.

In the meantime, many cancer patients are exercising their right to try.

@twc_health @McCulloughFund @IIAR_Journals @P_McCulloughMD @DrHarveyRisch @DrKellyVictory @jathorpmfm @drdrew @PeterGillooly @FosterCoulson

[Dr. Clown, PhD @DrClownPhD]

Enough internet for today...

[🦋 Amy 🦋 @Amy_90_x]

😭😭